Cargando…
Antibody fragments functionalized with non-canonical amino acids preserving structure and functionality - A door opener for new biological and therapeutic applications
Functionalization of proteins by incorporating reactive non-canonical amino acids (ncAAs) has been widely applied for numerous biological and therapeutic applications. The requirement not to lose the intrinsic properties of these proteins is often underestimated and not considered. Main purpose of t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686840/ https://www.ncbi.nlm.nih.gov/pubmed/38046162 http://dx.doi.org/10.1016/j.heliyon.2023.e22463 |
_version_ | 1785151851422810112 |
---|---|
author | Hanaee-Ahvaz, Hana Cserjan-Puschmann, Monika Mayer, Florian Tauer, Christopher Albrecht, Bernd Furtmüller, Paul G. Wiltschi, Birgit Hahn, Rainer Striedner, Gerald |
author_facet | Hanaee-Ahvaz, Hana Cserjan-Puschmann, Monika Mayer, Florian Tauer, Christopher Albrecht, Bernd Furtmüller, Paul G. Wiltschi, Birgit Hahn, Rainer Striedner, Gerald |
author_sort | Hanaee-Ahvaz, Hana |
collection | PubMed |
description | Functionalization of proteins by incorporating reactive non-canonical amino acids (ncAAs) has been widely applied for numerous biological and therapeutic applications. The requirement not to lose the intrinsic properties of these proteins is often underestimated and not considered. Main purpose of this study was to answer the question whether functionalization via residue-specific incorporation of the ncAA N(6)-[(2-Azidoethoxy) carbonyl]-l-lysine (Azk) influences the properties of the anti-tumor-necrosis-factor-α-Fab (FTN2). Therefore, FTN2(Azk) variants with different Azk incorporation sites were designed and amber codon suppression was used for production. The functionalized FTN2(Azk) variants were efficiently produced in fed-batch like μ-bioreactor cultivations in the periplasm of E. coli displaying correct structure and antigen binding affinities comparable to those of wild-type FTN2. Our FTN2(Azk) variants with reactive handles for diverse conjugates enable tracking of recombinant protein in the production cell, pharmacological studies and translation into new pharmaceutical applications. |
format | Online Article Text |
id | pubmed-10686840 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-106868402023-12-01 Antibody fragments functionalized with non-canonical amino acids preserving structure and functionality - A door opener for new biological and therapeutic applications Hanaee-Ahvaz, Hana Cserjan-Puschmann, Monika Mayer, Florian Tauer, Christopher Albrecht, Bernd Furtmüller, Paul G. Wiltschi, Birgit Hahn, Rainer Striedner, Gerald Heliyon Research Article Functionalization of proteins by incorporating reactive non-canonical amino acids (ncAAs) has been widely applied for numerous biological and therapeutic applications. The requirement not to lose the intrinsic properties of these proteins is often underestimated and not considered. Main purpose of this study was to answer the question whether functionalization via residue-specific incorporation of the ncAA N(6)-[(2-Azidoethoxy) carbonyl]-l-lysine (Azk) influences the properties of the anti-tumor-necrosis-factor-α-Fab (FTN2). Therefore, FTN2(Azk) variants with different Azk incorporation sites were designed and amber codon suppression was used for production. The functionalized FTN2(Azk) variants were efficiently produced in fed-batch like μ-bioreactor cultivations in the periplasm of E. coli displaying correct structure and antigen binding affinities comparable to those of wild-type FTN2. Our FTN2(Azk) variants with reactive handles for diverse conjugates enable tracking of recombinant protein in the production cell, pharmacological studies and translation into new pharmaceutical applications. Elsevier 2023-11-20 /pmc/articles/PMC10686840/ /pubmed/38046162 http://dx.doi.org/10.1016/j.heliyon.2023.e22463 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Research Article Hanaee-Ahvaz, Hana Cserjan-Puschmann, Monika Mayer, Florian Tauer, Christopher Albrecht, Bernd Furtmüller, Paul G. Wiltschi, Birgit Hahn, Rainer Striedner, Gerald Antibody fragments functionalized with non-canonical amino acids preserving structure and functionality - A door opener for new biological and therapeutic applications |
title | Antibody fragments functionalized with non-canonical amino acids preserving structure and functionality - A door opener for new biological and therapeutic applications |
title_full | Antibody fragments functionalized with non-canonical amino acids preserving structure and functionality - A door opener for new biological and therapeutic applications |
title_fullStr | Antibody fragments functionalized with non-canonical amino acids preserving structure and functionality - A door opener for new biological and therapeutic applications |
title_full_unstemmed | Antibody fragments functionalized with non-canonical amino acids preserving structure and functionality - A door opener for new biological and therapeutic applications |
title_short | Antibody fragments functionalized with non-canonical amino acids preserving structure and functionality - A door opener for new biological and therapeutic applications |
title_sort | antibody fragments functionalized with non-canonical amino acids preserving structure and functionality - a door opener for new biological and therapeutic applications |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686840/ https://www.ncbi.nlm.nih.gov/pubmed/38046162 http://dx.doi.org/10.1016/j.heliyon.2023.e22463 |
work_keys_str_mv | AT hanaeeahvazhana antibodyfragmentsfunctionalizedwithnoncanonicalaminoacidspreservingstructureandfunctionalityadooropenerfornewbiologicalandtherapeuticapplications AT cserjanpuschmannmonika antibodyfragmentsfunctionalizedwithnoncanonicalaminoacidspreservingstructureandfunctionalityadooropenerfornewbiologicalandtherapeuticapplications AT mayerflorian antibodyfragmentsfunctionalizedwithnoncanonicalaminoacidspreservingstructureandfunctionalityadooropenerfornewbiologicalandtherapeuticapplications AT tauerchristopher antibodyfragmentsfunctionalizedwithnoncanonicalaminoacidspreservingstructureandfunctionalityadooropenerfornewbiologicalandtherapeuticapplications AT albrechtbernd antibodyfragmentsfunctionalizedwithnoncanonicalaminoacidspreservingstructureandfunctionalityadooropenerfornewbiologicalandtherapeuticapplications AT furtmullerpaulg antibodyfragmentsfunctionalizedwithnoncanonicalaminoacidspreservingstructureandfunctionalityadooropenerfornewbiologicalandtherapeuticapplications AT wiltschibirgit antibodyfragmentsfunctionalizedwithnoncanonicalaminoacidspreservingstructureandfunctionalityadooropenerfornewbiologicalandtherapeuticapplications AT hahnrainer antibodyfragmentsfunctionalizedwithnoncanonicalaminoacidspreservingstructureandfunctionalityadooropenerfornewbiologicalandtherapeuticapplications AT striednergerald antibodyfragmentsfunctionalizedwithnoncanonicalaminoacidspreservingstructureandfunctionalityadooropenerfornewbiologicalandtherapeuticapplications |